In 2024, the clinical research data of HP518, an independent research and development innovative drug of the company's PROTC in the treatment of advanced prostate cancer (mCRPC), will be released at the American Society of Clinical Oncology (ASCO) Annual Meeting. HP518 is an orally administered, targeted protein degradation chimeric (PROTAC) drug independently developed by the company.
海创药业(688302.SH)：PROTAC在研药物HP518将在2024年美国临床肿瘤学会年会发布临床数据
Haichuang Pharmaceutical (688302.SH): PROTAC drug under development HP518 will release clinical data at the 2024 American Society of Clinical Oncology Annual Meeting
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.